DDInter1718 DDInter1180
Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Sufentanil {u} (Compound) resembles {v} (Compound) Anileridine
Sufentanil {u} (Compound) binds {v} (Gene) OPRM1
Sufentanil {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Sufentanil {u} (Compound) causes {v} (Side Effect) Vomiting
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desmopressin
Sufentanil {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Sufentanil {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Sufentanil (Compound) resembles Anileridine (Compound)
Sufentanil (Compound) binds OPRM1 (Gene)
Sufentanil (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Sufentanil (Compound) causes Vomiting (Side Effect)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin
Sufentanil may lead to a major life threatening interaction when taken with Dexfenfluramine
Sufentanil may lead to a major life threatening interaction when taken with Naltrexone